Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of TAK-385 10, 20, and 40 mg (p.o.) in the Treatment of Endometriosis

Next Previous
Trial Profile

A Phase II, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of TAK-385 10, 20, and 40 mg (p.o.) in the Treatment of Endometriosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 May 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Relugolix (Primary) ; Leuprorelin
  • Indications Endometriosis
  • Focus Therapeutic Use
  • Sponsors Takeda

Most Recent Events

  • 19 May 2017 Primary endpoint (Pain intensity (Score for pelvic pain as measured by the Visual Analogue Scale (VAS), assessed at week 12 (one menstrual cycle), also assessed as a secondary endpoint.)) has been met, according to a Myovant Sciences media release.
  • 19 May 2017 According to a Myovant Sciences media release, results from this trial were presented at the at the 2017 World Congress on Endometriosis.
  • 19 May 2017 Results published in a Myovant Sciences media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top